Vivek S. Purohit

1.9k total citations · 2 hit papers
52 papers, 1.3k citations indexed

About

Vivek S. Purohit is a scholar working on Dermatology, Hematology and Molecular Biology. According to data from OpenAlex, Vivek S. Purohit has authored 52 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Dermatology, 11 papers in Hematology and 10 papers in Molecular Biology. Recurrent topics in Vivek S. Purohit's work include Dermatology and Skin Diseases (12 papers), Hemophilia Treatment and Research (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Vivek S. Purohit is often cited by papers focused on Dermatology and Skin Diseases (12 papers), Hemophilia Treatment and Research (10 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). Vivek S. Purohit collaborates with scholars based in United States, United Kingdom and Canada. Vivek S. Purohit's co-authors include Robert Bissonnette, Sathyamangalam V. Balasubramanian, Melinda Gooderham, Carla Mamolo, Kim Papp, C. Russell Middaugh, William C. Ports, Maitreyi Raman, Yves Poulin and C. Wang and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Hepatology.

In The Last Decade

Vivek S. Purohit

50 papers receiving 1.3k citations

Hit Papers

Topical tofacitinib for atopic dermatitis: a phase II a r... 2016 2026 2019 2022 2016 2023 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
    2016 320 citations Robert Bissonnette, Kim Papp et al. British Journal of Dermatology profile →
  2. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
    2023 134 citations Brett King, Xingqi Zhang et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vivek S. Purohit United States 18 628 376 306 225 214 52 1.3k
Karen Page United States 14 211 0.3× 44 0.1× 280 0.9× 129 0.6× 127 0.6× 24 821
Scott Steward-Tharp United States 8 96 0.2× 24 0.1× 752 2.5× 213 0.9× 258 1.2× 20 1.3k
Fumi Miyagawa Japan 15 119 0.2× 47 0.1× 587 1.9× 240 1.1× 215 1.0× 52 1.2k
Peter Kaskel Germany 18 271 0.4× 61 0.2× 205 0.7× 541 2.4× 95 0.4× 43 1.5k
Martina Sanlorenzo Italy 23 269 0.4× 42 0.1× 380 1.2× 583 2.6× 33 0.2× 53 1.6k
John C. Minnerly United States 8 57 0.1× 25 0.1× 229 0.7× 153 0.7× 278 1.3× 11 745
Igor Vujic Austria 22 227 0.4× 18 0.0× 338 1.1× 488 2.2× 73 0.3× 50 1.4k
Patricia Bacon United States 15 152 0.2× 22 0.1× 314 1.0× 507 2.3× 31 0.1× 22 985
Leslie G. Ratkay Canada 14 44 0.1× 67 0.2× 263 0.9× 168 0.7× 134 0.6× 25 775
Steven J. Glassman Canada 13 320 0.5× 19 0.1× 151 0.5× 91 0.4× 38 0.2× 37 680

Countries citing papers authored by Vivek S. Purohit

Since Specialization
Citations

This map shows the geographic impact of Vivek S. Purohit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vivek S. Purohit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vivek S. Purohit more than expected).

Fields of papers citing papers by Vivek S. Purohit

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vivek S. Purohit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vivek S. Purohit. The network helps show where Vivek S. Purohit may publish in the future.

Co-authorship network of co-authors of Vivek S. Purohit

This figure shows the co-authorship network connecting the top 25 collaborators of Vivek S. Purohit. A scholar is included among the top collaborators of Vivek S. Purohit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vivek S. Purohit. Vivek S. Purohit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sagawa, Kazuko, Vivek S. Purohit, Vu Le, et al.. (2025). Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects. The AAPS Journal. 27(3). 71–71. 4 indexed citations
2.
3.
4.
Bauman, Jonathan, Angela C. Doran, Brian Hee, et al.. (2024). The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans. Drug Metabolism and Disposition. 52(10). 1124–1136. 7 indexed citations
5.
6.
7.
Purohit, Vivek S., et al.. (2023). Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development. Clinical Pharmacokinetics. 62(12). 1765–1779. 11 indexed citations
8.
King, Brett, Xingqi Zhang, Jacek C. Szepietowski, et al.. (2023). A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata. Immunotherapy. 15(14). 1093–1103. 4 indexed citations
9.
King, Brett, Xingqi Zhang, Jacek C. Szepietowski, et al.. (2023). Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial. The Lancet. 401(10387). 1518–1529. 134 indexed citations breakdown →
10.
Purohit, Vivek S., Steve Riley, Huaming Tan, & William C. Ports. (2020). Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis. The Journal of Clinical Pharmacology. 60(10). 1344–1354. 6 indexed citations
11.
Schlessinger, Joel, Richard Gower, John Su, et al.. (2020). Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology. 21(2). 275–284. 66 indexed citations
12.
Purohit, Vivek S., J.L. Werth, D. Graham, & Timothy Nicholas. (2020). 512 Patient and disease characteristic predictors of systemic exposure to crisaborole. Journal of Investigative Dermatology. 140(7). S70–S70. 1 indexed citations
13.
Bissonnette, Robert, Ana B. Pavel, Aisleen Diaz, et al.. (2019). Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial. Journal of Allergy and Clinical Immunology. 144(5). 1274–1289. 95 indexed citations
14.
Berry‐Bibee, Erin, Diana Blithe, Ruth S. Day, et al.. (2018). FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”. The Journal of Clinical Pharmacology. 58(12). 1655–1665. 15 indexed citations
15.
Bissonnette, Robert, Kim Papp, Yves Poulin, et al.. (2016). Topical tofacitinib for atopic dermatitis: a phase II a randomized trial. British Journal of Dermatology. 175(5). 902–911. 320 indexed citations breakdown →
16.
Polli, James E., Jack Cook, Barbara M. Davit, et al.. (2012). Summary Workshop Report: Facilitating Oral Product Development and Reducing Regulatory Burden Through Novel Approaches to Assess Bioavailability/Bioequivalence. The AAPS Journal. 14(3). 627–638. 15 indexed citations
17.
Jacobson, Ira M., Paul J. Pockros, Jacob Lalezari, et al.. (2010). 2005 VIROLOGIC RESPONSE RATES FOLLOWING 4 WEEKS OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONICALLY-INFECTED HCV GENOTYPE-1 PATIENTS. Journal of Hepatology. 52. S465–S465. 18 indexed citations
18.
Purohit, Vivek S., et al.. (2008). Passive Transfer of Polyethylene Glycol to Liposomal-Recombinant Human FVIII Enhances its Efficacy in a Murine Model for Hemophilia A. Journal of Pharmaceutical Sciences. 97(9). 3753–3764. 12 indexed citations
19.
Purohit, Vivek S., et al.. (2007). O-phospho-L-serine, multi-functional excipient for B domain deleted recombinant factor VIII. The AAPS Journal. 9(2). E251–E259. 12 indexed citations
20.
Purohit, Vivek S., et al.. (2003). Topology of factor VIII bound to phosphatidylserine-containing model membranes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 1617(1-2). 31–38. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Karen Page Breakdown of academic impact, for papers by Scott Steward-Tharp Breakdown of academic impact, for papers by Fumi Miyagawa Breakdown of academic impact, for papers by Peter Kaskel Breakdown of academic impact, for papers by Martina Sanlorenzo Breakdown of academic impact, for papers by John C. Minnerly Breakdown of academic impact, for papers by Igor Vujic Breakdown of academic impact, for papers by Patricia Bacon Breakdown of academic impact, for papers by Leslie G. Ratkay Breakdown of academic impact, for papers by Steven J. Glassman
Rankless by CCL
2026